Sie sind bereits eingeloggt. Klicken Sie auf 2. tolino select Abo, um fortzufahren.
Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei bücher.de, um das eBook-Abo tolino select nutzen zu können.
Drug-Drug Interactions in Pharmaceutical Development comprehensively reviews the relevant science, industrial practice, and regulatory agency positions on drug-drug interactions. It focuses on the evaluation of potential drug-drug interactions, allowing researchers to address risk factors before a drug is put to market. The book covers both clinical and nonclinical aspects for understanding drug-drug interactions as well as in vitro and in vivo studies for use in studying interactions at the drug discovery stage.
Drug-Drug Interactions in Pharmaceutical Development comprehensively reviews the relevant science, industrial practice, and regulatory agency positions on drug-drug interactions. It focuses on the evaluation of potential drug-drug interactions, allowing researchers to address risk factors before a drug is put to market. The book covers both clinical and nonclinical aspects for understanding drug-drug interactions as well as in vitro and in vivo studies for use in studying interactions at the drug discovery stage.
Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.
Albert P. Li is the President and CEO of In Vitro ADMET Laboratories, LLC (www.invitroadmet.com), and Advanced Pharmaceutical Sciences, Inc. (www.apsciences.com), and the cofounder, Chairman, and CSO of the ADMET Group (www.admetgroup.com). Dr. Li has over twenty-five years in the drug development industry, is a distinguished international speaker in the field, and has over 150 publications. He has edited several books.
Inhaltsangabe
Preface. Contributors. 1 In Vitro Evaluation of Metabolic Drug-Drug Interactions: Concepts and Practice (Albert P. Li). 1.1 Introduction. 1.2 Mechanisms of Adverse Drug-Drug Interactions. 1.3 Drug Metabolism. 1.4 CYP Isoforms. 1.5 Human In Vitro Experimental Systems for Drug Metabolism. 1.6 Mechanisms of Metabolic Drug-Drug Interactions. 1.7 Mechanism-Based Approach for Evaluation of Drug-Drug Interaction Potential. 1.8 Experimental Approaches for In Vitro Evaluation of Drug-Drug Interaction Potential. 1.9 Data Interpretation. 1.10 Conclusion. References. 2 In Vitro Approaches to Anticipating Clinical Drug Interactions (Laurie P. Volak, David J. Greenblatt, and Lisa L. von Moltke). 2.1 In Vitro Systems for Human CYP450 Metabolism. 2.2 Analysis of Data from In Vitro Systems. 2.3 Use of In Vitro Kinetic Data to Predict In Vivo Clearance. 2.4 Use of In Vitro Kinetic Data to Predict Drug-Drug Interactions. 2.5 Consideration of Non-CYP Enzymatic Systems. 2.6 Summary. 2.7 Acknowledgments. References. 3 Inhibition of Drug-Metabolizing Enzymes and Drug-Drug Interactions in Drug Discovery and Development (R. Scott Obach). 3.1 Introduction. 3.2 Laboratory Approaches Inhibiting Drug-Metabolizing Enzymes. 3.3 Selection of Substrates for Inhibition Experiments in Drug Metabolism. 3.4 Inhibition of Drug-Metabolizing Enzymes in Drug Discovery and Development. 3.5 Summary. References. 4 Mechanism-Based CYP Inhibition: Enzyme Kinetics, Assays, and Prediction of Human Drug-Drug Interactions (Magang Shou). 4.1 Kinetic Model for Mechanism-Based Inhibition. 4.2 Methodological Measurements of Kinetic Parameters. 4.3 Incubation. 4.4 Prediction of Human DDIs from In Vitro MBI Data. 4.5 Acknowledgments. References. 5 Genomic Approaches To Drug-Drug Interactions (Yi Yang and Jeffrey F. Waring). 5.1 Introduction. 5.2 DNA Microarrays. 5.3 Genomic Application Toward the Prediction of DDIs. 5.4 Genomics Approach to Decipher the Molecular Basis of DDI: Nuclear Receptors. 5.5 Genomic Approaches to Address the Genetic Variability in DDIs. 5.6 Conclusion. References. 6 Transporters and Drug Interactions (Yoshihisa Shitara, Toshiharu Horie, and Yuichi Sugiyama) 6.1 Introduction. 6.2 Interactions Involving Liver Transporters. 6.3 Interactions in Intestine Transporters. 6.4 Drug Toxicity Involving Drug Transporters. 6.5 Drugs that Affect the Expression or Localization of Transporters. 6.6 Conclusion. References. 7 Transporter-Mediated Drug Interactions: Molecular Mechanisms and Clinical Implications (Jiunn H. Lin). 7.1 Introduction. 7.2 Tissue Distribution and Cellular Location of Transporters. 7.3 Molecular Mechanisms for Transporter Inhibition and Induction. 7.4 Drug Interactions Caused by Transporter Inhibition and Induction. 7.5 Clinical Significance of Transporter-Mediated Drug Interactions. 7.6 Conclusion. References. 8 Recent Case Studies of Clinically Significant Drug-Drug Interactions and the Limits of In Vitro Prediction Methodology (René H. Levy, Isabelle Ragueneau-Majlessi, and Carol Collins). 8.1 Introduction. 8.2 Case Studies. References. 9 U.S. Regulatory Perspective: Drug-Drug Interactions (John Strong and Shiew-Mei Huang). 9.1 Introduction. 9.2 An Integrated Approach. 9.3 Methods for Evaluating Metabolic Clearance In Vitro. 9.4 In Vivo Approaches. 9.5 Clinical Cases. 9.6 Regulatory Considerations. 9.7 Labeling. 9.8 Summary. References. 10 Herbal Drug Interactions--A Canadian Perspective (Brian C. Foster) 10.1 Introduction. 10.2 Interaction Risk Determination. 10.3 NHP Products. 10.4 Disposition. 10.5 PD and PK interactions. 10.6 Action. References. Index. Wiley Series in Drug Discovery and Development.
Preface. Contributors. 1 In Vitro Evaluation of Metabolic Drug-Drug Interactions: Concepts and Practice (Albert P. Li). 1.1 Introduction. 1.2 Mechanisms of Adverse Drug-Drug Interactions. 1.3 Drug Metabolism. 1.4 CYP Isoforms. 1.5 Human In Vitro Experimental Systems for Drug Metabolism. 1.6 Mechanisms of Metabolic Drug-Drug Interactions. 1.7 Mechanism-Based Approach for Evaluation of Drug-Drug Interaction Potential. 1.8 Experimental Approaches for In Vitro Evaluation of Drug-Drug Interaction Potential. 1.9 Data Interpretation. 1.10 Conclusion. References. 2 In Vitro Approaches to Anticipating Clinical Drug Interactions (Laurie P. Volak, David J. Greenblatt, and Lisa L. von Moltke). 2.1 In Vitro Systems for Human CYP450 Metabolism. 2.2 Analysis of Data from In Vitro Systems. 2.3 Use of In Vitro Kinetic Data to Predict In Vivo Clearance. 2.4 Use of In Vitro Kinetic Data to Predict Drug-Drug Interactions. 2.5 Consideration of Non-CYP Enzymatic Systems. 2.6 Summary. 2.7 Acknowledgments. References. 3 Inhibition of Drug-Metabolizing Enzymes and Drug-Drug Interactions in Drug Discovery and Development (R. Scott Obach). 3.1 Introduction. 3.2 Laboratory Approaches Inhibiting Drug-Metabolizing Enzymes. 3.3 Selection of Substrates for Inhibition Experiments in Drug Metabolism. 3.4 Inhibition of Drug-Metabolizing Enzymes in Drug Discovery and Development. 3.5 Summary. References. 4 Mechanism-Based CYP Inhibition: Enzyme Kinetics, Assays, and Prediction of Human Drug-Drug Interactions (Magang Shou). 4.1 Kinetic Model for Mechanism-Based Inhibition. 4.2 Methodological Measurements of Kinetic Parameters. 4.3 Incubation. 4.4 Prediction of Human DDIs from In Vitro MBI Data. 4.5 Acknowledgments. References. 5 Genomic Approaches To Drug-Drug Interactions (Yi Yang and Jeffrey F. Waring). 5.1 Introduction. 5.2 DNA Microarrays. 5.3 Genomic Application Toward the Prediction of DDIs. 5.4 Genomics Approach to Decipher the Molecular Basis of DDI: Nuclear Receptors. 5.5 Genomic Approaches to Address the Genetic Variability in DDIs. 5.6 Conclusion. References. 6 Transporters and Drug Interactions (Yoshihisa Shitara, Toshiharu Horie, and Yuichi Sugiyama) 6.1 Introduction. 6.2 Interactions Involving Liver Transporters. 6.3 Interactions in Intestine Transporters. 6.4 Drug Toxicity Involving Drug Transporters. 6.5 Drugs that Affect the Expression or Localization of Transporters. 6.6 Conclusion. References. 7 Transporter-Mediated Drug Interactions: Molecular Mechanisms and Clinical Implications (Jiunn H. Lin). 7.1 Introduction. 7.2 Tissue Distribution and Cellular Location of Transporters. 7.3 Molecular Mechanisms for Transporter Inhibition and Induction. 7.4 Drug Interactions Caused by Transporter Inhibition and Induction. 7.5 Clinical Significance of Transporter-Mediated Drug Interactions. 7.6 Conclusion. References. 8 Recent Case Studies of Clinically Significant Drug-Drug Interactions and the Limits of In Vitro Prediction Methodology (René H. Levy, Isabelle Ragueneau-Majlessi, and Carol Collins). 8.1 Introduction. 8.2 Case Studies. References. 9 U.S. Regulatory Perspective: Drug-Drug Interactions (John Strong and Shiew-Mei Huang). 9.1 Introduction. 9.2 An Integrated Approach. 9.3 Methods for Evaluating Metabolic Clearance In Vitro. 9.4 In Vivo Approaches. 9.5 Clinical Cases. 9.6 Regulatory Considerations. 9.7 Labeling. 9.8 Summary. References. 10 Herbal Drug Interactions--A Canadian Perspective (Brian C. Foster) 10.1 Introduction. 10.2 Interaction Risk Determination. 10.3 NHP Products. 10.4 Disposition. 10.5 PD and PK interactions. 10.6 Action. References. Index. Wiley Series in Drug Discovery and Development.
Rezensionen
"I am pleased to have read this book from cover-to-cover. I will value owning it and keep it near the front of my bookshelf" ( Good Clinical Practice Journal , June 2008)
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Shop der buecher.de GmbH & Co. KG Bürgermeister-Wegele-Str. 12, 86167 Augsburg Amtsgericht Augsburg HRA 13309
